<DOC>
	<DOCNO>NCT00193245</DOCNO>
	<brief_summary>In trial evaluate compare efficacy toxicity oral topotecan intravenous docetaxel second-line treatment patient non-small cell lung cancer .</brief_summary>
	<brief_title>Oral Topotecan Versus Docetaxel Second-Line Treatment Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Upon determination eligibility , patient randomly assign one two treatment arm : - Topotecan - Docetaxel For ever 2 patient treat , 1 receive treatment A ( Topotecan ) 1 receive treatment B ( Docetaxel ) . The study blind patient doctor know treatment assign .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>To include study , must meet following criterion : Relapsed Progressive Disease Stage IIIB ( candidate combine modality ) IV No one prior chemotherapy regimen Able perform activity daily live without assistance Measurable disease outside radiation port Adequate bone marrow , liver kidney function Must understand study sign inform consent prior enrollment You participate study follow apply : Prior treatment Topotecan Docetaxel Uncontrolled brain metastasis Moderate peripheral neuropathy Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>